Shares of Bluebird Bio fell over 13% in premarket trading after the company said it would sell its common stock in a public offering.
The Somerville, Mass.-based company said it would sell $150 million of common stock. Bluebird said the underwriters would have a 30-day option to purchase up to an additional $22.5 million shares.
The company said it would use the proceeds to manufacture its approved gene therapies and for working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments